E Sabaté

9.2k total citations · 1 hit paper
11 papers, 1.9k citations indexed

About

E Sabaté is a scholar working on Pulmonary and Respiratory Medicine, Statistics and Probability and Infectious Diseases. According to data from OpenAlex, E Sabaté has authored 11 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Statistics and Probability and 2 papers in Infectious Diseases. Recurrent topics in E Sabaté's work include HIV/AIDS Research and Interventions (2 papers), Economic and Financial Impacts of Cancer (2 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). E Sabaté is often cited by papers focused on HIV/AIDS Research and Interventions (2 papers), Economic and Financial Impacts of Cancer (2 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). E Sabaté collaborates with scholars based in Switzerland, United States and France. E Sabaté's co-authors include Patricia V. Burkhart, Sabina De Geest, L. Elit, Julia Brown, Andrés Cervantes, Ann Marie Swart, Timothy Perren, Philip Beale, Mark S. Carey and Gunnar B. Kristensen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and The Lancet Oncology.

In The Last Decade

E Sabaté

8 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence to Long‐Term Therapies: Evidence for Action

2003 1.8k citations Patricia V. Burkhart, E Sabaté Journal of Nursing Scholarship profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E Sabaté Switzerland	5	805	327	315	310	274	11	1.9k
Marie T. Brown United States	6	878 1.1×	399 1.2×	331 1.1×	266 0.9×	272 1.0×	11	1.7k
Patricia V. Burkhart United States	15	927 1.2×	368 1.1×	442 1.4×	378 1.2×	401 1.5×	23	2.5k
Valerie Morrison United Kingdom	11	966 1.2×	336 1.0×	217 0.7×	371 1.2×	267 1.0×	17	1.7k
Chris Cotoi Canada	8	1.0k 1.3×	440 1.3×	408 1.3×	334 1.1×	311 1.1×	10	1.9k
Arun Keepanasseril Canada	10	1.1k 1.4×	460 1.4×	449 1.4×	398 1.3×	353 1.3×	32	2.3k
Marie Paule Schneider Switzerland	20	627 0.8×	380 1.2×	195 0.6×	265 0.9×	208 0.8×	110	1.7k
Emily Fargher United Kingdom	9	1.2k 1.5×	410 1.3×	237 0.8×	425 1.4×	319 1.2×	12	2.1k
Anuja Roy United States	11	823 1.0×	276 0.8×	148 0.5×	359 1.2×	219 0.8×	41	2.2k
David P. Nau United States	18	932 1.2×	508 1.6×	276 0.9×	261 0.8×	253 0.9×	49	2.0k
Xiaomei Yao Canada	19	1.1k 1.3×	545 1.7×	360 1.1×	406 1.3×	346 1.3×	56	2.7k

Countries citing papers authored by E Sabaté

Since Specialization

Citations

This map shows the geographic impact of E Sabaté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Sabaté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Sabaté more than expected).

Fields of papers citing papers by E Sabaté

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E Sabaté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Sabaté. The network helps show where E Sabaté may publish in the future.

Co-authorship network of co-authors of E Sabaté

This figure shows the co-authorship network connecting the top 25 collaborators of E Sabaté. A scholar is included among the top collaborators of E Sabaté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Sabaté. E Sabaté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Rochau, Ursula, et al.. (2021). Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. Medical Decision Making. 42(2). 194–207. 1 indexed citations

2.

Rochau, Ursula, et al.. (2021). Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. PubMed. 42(2). 194–207. 1 indexed citations

3.

Rochau, Ursula, et al.. (2014). Estimating Crossover Bias In A Randomized Clinical Trial Of Ovarian Cancer Treatment. Value in Health. 17(7). A564–A564. 1 indexed citations

4.

Stark, Dan, Matthew Nankivell, Éric Pujade-Lauraine, et al.. (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology. 14(3). 236–243. 95 indexed citations

5.

Gyldmark, Marlene, et al.. (2009). PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE. Value in Health. 12(3). A49–A49.

6.

Holmberg, Christine, et al.. (2009). PCN70 MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN. Value in Health. 12(3). A49–A49.

7.

Sabaté, E, et al.. (2009). PCN51 PROJECTED LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH BEVACIZUMAB TREATMENT IN PATIENTS WITH ADJUVANT TRIPLENEGATIVE BREAST CANCER TO INFORM EARLY DECISION MAKING. Value in Health. 12(3). A45–A46.

8.

Mickisch, G., et al.. (2008). Costs of managing side effects in the treatment of first line metastatic renal cell carcinoma (mRCC) in Germany, France, and UK: Bevacizumab (BEV) + interferon alpha-2a (IFN) compared with sunitinib. Journal of Clinical Oncology. 26(15_suppl). 5110–5110. 5 indexed citations

9.

Sabaté, E & Sabina De Geest. (2004). Adherence to Long‐Term Therapies Management: A Call for Cardiovascular Nursing Managers and Policymakers. Progress in Cardiovascular Nursing. 19(1). 28–29. 15 indexed citations

10.

Sabaté, E, et al.. (2003). Adherence to Heroin Dependence Therapies and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Infection Rates among Drug Abusers. Clinical Infectious Diseases. 37(s5). S464–S467. 10 indexed citations

11.

Burkhart, Patricia V. & E Sabaté. (2003). Adherence to Long‐Term Therapies: Evidence for Action. Journal of Nursing Scholarship. 35(3). 207–207. 1801 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact